4-phenylbutyric acid has been researched along with simvastatin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ajitkumar, S; Murugan Girija, D; Ranga Rao, S; Subbarayan, R | 1 |
1 review(s) available for 4-phenylbutyric acid and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for 4-phenylbutyric acid and simvastatin
| Article | Year |
|---|---|
4PBA strongly attenuates endoplasmic reticulum stress, fibrosis, and mitochondrial apoptosis markers in cyclosporine treated human gingival fibroblasts.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Survival; Cells, Cultured; Cyclosporine; Cytoprotection; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Fibroblasts; Fibrosis; Gingiva; Gingival Overgrowth; Humans; Melatonin; Mitochondria; Phenylbutyrates; Signal Transduction; Simvastatin | 2018 |